108 related articles for article (PubMed ID: 20669003)
1. RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults.
Wen PY; van den Bent M; Youssef G; Cloughesy TF; Ellingson BM; Weller M; Galanis E; Barboriak DP; de Groot J; Gilbert MR; Huang R; Lassman AB; Mehta M; Molinaro AM; Preusser M; Rahman R; Shankar LK; Stupp R; Villanueva-Meyer JE; Wick W; Macdonald DR; Reardon DA; Vogelbaum MA; Chang SM
J Clin Oncol; 2023 Nov; 41(33):5187-5199. PubMed ID: 37774317
[TBL] [Abstract][Full Text] [Related]
2. Response Assessment in Neuro-Oncology Clinical Trials.
Wen PY; Chang SM; Van den Bent MJ; Vogelbaum MA; Macdonald DR; Lee EQ
J Clin Oncol; 2017 Jul; 35(21):2439-2449. PubMed ID: 28640707
[TBL] [Abstract][Full Text] [Related]
3. A Neuroradiologist's Guide to Operationalizing the Response Assessment in Neuro-Oncology (RANO) Criteria Version 2.0 for Gliomas in Adults.
Ellingson BM; Sanvito F; Cloughesy TF; Huang RY; Villanueva-Meyer JE; Pope WB; Barboriak DP; Shankar LK; Smits M; Kaufmann TJ; Boxerman JL; Weller M; Galanis E; Groot J; Gilbert MR; Lassman AB; Shiroishi MS; Nabavizadeh A; Mehta M; Stupp R; Wick W; Reardon DA; Vogelbaum MA; van den Bent M; Chang SM; Wen PY
AJNR Am J Neuroradiol; 2024 Jun; ():. PubMed ID: 38926092
[TBL] [Abstract][Full Text] [Related]
4. Updated Response Assessment in Neuro-Oncology (RANO) for Gliomas.
Youssef G; Wen PY
Curr Neurol Neurosci Rep; 2024 Feb; 24(2):17-25. PubMed ID: 38170429
[TBL] [Abstract][Full Text] [Related]
5. Response Assessment in Neuro-Oncology (RANO): more than imaging criteria for malignant glioma.
Chang SM; Wen PY; Vogelbaum MA; Macdonald DR; van den Bent MJ
Neurooncol Pract; 2015 Dec; 2(4):205-209. PubMed ID: 31386074
[TBL] [Abstract][Full Text] [Related]
6. PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group.
Albert NL; Galldiks N; Ellingson BM; van den Bent MJ; Chang SM; Cicone F; de Groot J; Koh ES; Law I; Le Rhun E; Mair MJ; Minniti G; Rudà R; Scott AM; Short SC; Smits M; Suchorska B; Tolboom N; Traub-Weidinger T; Tonn JC; Verger A; Weller M; Wen PY; Preusser M
Lancet Oncol; 2024 Jan; 25(1):e29-e41. PubMed ID: 38181810
[TBL] [Abstract][Full Text] [Related]
7. The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria.
Nayak L; DeAngelis LM; Brandes AA; Peereboom DM; Galanis E; Lin NU; Soffietti R; Macdonald DR; Chamberlain M; Perry J; Jaeckle K; Mehta M; Stupp R; Muzikansky A; Pentsova E; Cloughesy T; Iwamoto FM; Tonn JC; Vogelbaum MA; Wen PY; van den Bent MJ; Reardon DA
Neuro Oncol; 2017 May; 19(5):625-635. PubMed ID: 28453751
[TBL] [Abstract][Full Text] [Related]
8. Glioma surveillance imaging: current strategies, shortcomings, challenges and outlook.
Abdalla G; Hammam A; Anjari M; D'Arco DF; Bisdas DS
BJR Open; 2020; 2(1):20200009. PubMed ID: 33178973
[TBL] [Abstract][Full Text] [Related]
9. Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group.
Arvold ND; Armstrong TS; Warren KE; Chang SM; DeAngelis LM; Blakeley J; Chamberlain MC; Dunbar E; Loong HH; Macdonald DR; Reardon DA; Vogelbaum MA; Yuan Y; Weller M; van den Bent M; Wen PY
Neuro Oncol; 2018 Jun; 20(7):897-906. PubMed ID: 29788429
[TBL] [Abstract][Full Text] [Related]
10. RAPNO efforts in Brain Tumour Outcomes.
Virani QU; Javed Z; Shamim MS
J Pak Med Assoc; 2024 May; 74(5):1005-1006. PubMed ID: 38783459
[TBL] [Abstract][Full Text] [Related]
11. Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD).
Helfer JL; Wen PY; Blakeley J; Gilbert MR; Armstrong TS
Neuro Oncol; 2016 Mar; 18 Suppl 2(Suppl 2):ii26-ii36. PubMed ID: 26989130
[TBL] [Abstract][Full Text] [Related]
12. RANO 2.0: The revised Response Assessment in Neuro-Oncology (RANO) criteria for high- and low-grade glial tumors in adults designed for the future.
Wen PY; van den Bent M; Vogelbaum MA; Chang SM
Neuro Oncol; 2024 Jan; 26(1):2-4. PubMed ID: 37774741
[No Abstract] [Full Text] [Related]
13. Evolution and implementation of radiographic response criteria in neuro-oncology.
Ramakrishnan D; von Reppert M; Krycia M; Sala M; Mueller S; Aneja S; Nabavizadeh A; Galldiks N; Lohmann P; Raji C; Ikuta I; Memon F; Weinberg BD; Aboian MS
Neurooncol Adv; 2023; 5(1):vdad118. PubMed ID: 37860269
[TBL] [Abstract][Full Text] [Related]
14. Summary of Key Points of the Response Assessment in Neuro-Oncology (RANO) 2.0.
Won SE; Suh CH; Kim S; Park HJ; Kim KW
Korean J Radiol; 2024 May; 25(5):407-411. PubMed ID: 38627876
[No Abstract] [Full Text] [Related]
15. Measure what is measurable: PET RANO 1.0 criteria for interpretation of amino acid PET of diffuse gliomas.
Albert NL; Preusser M
Neuro Oncol; 2024 Mar; 26(3):401-402. PubMed ID: 38165287
[No Abstract] [Full Text] [Related]
16. Impact of standard care on elderly glioblastoma patients.
Lapointe S; Florescu M; Simonyan D; Michaud K
Neurooncol Pract; 2017 Mar; 4(1):4-14. PubMed ID: 31385982
[TBL] [Abstract][Full Text] [Related]
17. [New criteria for assessment of response to treatment of gliomas].
Weber MA
Radiologe; 2012 Apr; 52(4):317-9. PubMed ID: 22434414
[No Abstract] [Full Text] [Related]
18. Neuroradiological response criteria for high-grade gliomas.
Lutz K; Radbruch A; Wiestler B; Bäumer P; Wick W; Bendszus M
Clin Neuroradiol; 2011 Nov; 21(4):199-205. PubMed ID: 21681688
[TBL] [Abstract][Full Text] [Related]
19. [Neuroradiological response criteria for malignant gliomas].
Bendszus M; Platten M
Nervenarzt; 2010 Aug; 81(8):950-5. PubMed ID: 20669003
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
